236 studies found for:    Open Studies | United States, Vermont
Show Display Options
Rank Status Study
21 Unknown  Neoadjuvant Cisplatin/Docetaxel (CDDP/TXT) and Chemoradiation for Head and Neck Cancer
Condition: Head and Neck Neoplasms
Interventions: Drug: Docetaxel/cisplatin;   Radiation: Radiotherapy;   Drug: Carboplatin
22 Recruiting Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
Conditions: Clear Cell Adenocarcinoma;   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Mucinous Adenocarcinoma;   Ovarian Brenner Tumor;   Ovarian Clear Cell Adenocarcinofibroma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Adenocarcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Carcinoma;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Biological: Bevacizumab;   Drug: Carboplatin;   Drug: Docetaxel;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment
23 Recruiting Long Term, Extension Study of the Safety and Efficacy of AVP-786 (Deuterated [d6] Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Condition: Agitation in Alzheimer's Disease
Intervention: Drug: AVP-786
24 Recruiting Pre-Emptive Analgesia in Ano-Rectal Surgery
Conditions: Hemorrhoids;   Fissure in Ano;   Rectal Fistula;   Anal Condyloma
Interventions: Drug: Gabapentin;   Drug: Ketamine;   Drug: Acetaminophen;   Drug: Dexamethasone;   Drug: Placebo
25 Recruiting Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Conditions: Recurrent Melanoma of the Skin;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Biological: Sargramostim
26 Recruiting Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
Conditions: Diabetes Mellitus, Type 2;   Diabetic Nephropathy
Interventions: Drug: Canagliflozin;   Drug: Placebo
27 Recruiting Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Olaparib;   Drug: Placebo
28 Recruiting Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.
Conditions: COPD;   Chronic Obstructive Pulmonary Disease;   Moderate to Very Severe COPD
Interventions: Drug: Aclidinium Bromide;   Drug: Placebo
29 Recruiting Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Invasive Ductal Breast Carcinoma;   Invasive Lobular Breast Carcinoma;   Recurrent Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: fulvestrant;   Drug: anastrozole
30 Recruiting Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: enzalutamide;   Drug: abiraterone;   Drug: prednisone
31 Recruiting Study Of Diabetic Nephropathy With Atrasentan
Condition: Diabetic Nephropathy
Interventions: Drug: Atrasentan;   Drug: Placebo
32 Recruiting Connect® MDS/AML Disease Registry
Conditions: Myelodysplastic Syndromes;   Acute Myeloid Leukemia
Intervention:
33 Recruiting Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: Ipilimumab;   Other: Quality-of-Life Assessment;   Biological: Recombinant Interferon Alfa-2b
34 Recruiting A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer
Conditions: Non-Small Cell Lung Cancer (ALK-positive);   Non-Small Cell Lung Cancer (c-Met Dependent);   Non-Small Cell Lung Cancer (ROS Marker Positive);   Systemic Anaplastic Large-Cell Lymphoma;   Advanced Malignancies (Except Leukemia)
Interventions: Drug: PF-02341066;   Drug: Rifampin;   Drug: Itraconazole
35 Recruiting Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Adenosquamous Carcinoma;   Endometrial Clear Cell Adenocarcinoma;   Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation;   Endometrial Serous Adenocarcinoma;   Recurrent Uterine Corpus Carcinoma
Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Cisplatin;   Radiation: Intensity-Modulated Radiation Therapy;   Radiation: Internal Radiation Therapy
36 Recruiting Does Abstinence From E-cigarettes Produce Withdrawal Symptoms?
Condition: Substance Withdrawal Syndrome
Intervention: Behavioral: Abstinence from e-cigarettes
37 Recruiting Bemobile Intervention to Support Physical Activity in Cancer Survivors
Condition: Cancer
Intervention: Behavioral: Bemobile
38 Recruiting A Pilot Study of Combined Cycle Ergometry and Amino Acids in the ICU
Condition: Acute Respiratory Failure
Intervention: Other: IV amino acids and in-bed cycle ergometry
39 Recruiting A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia
Condition: Alzheimer's Disease
Interventions: Drug: LY3202626;   Drug: Placebo
40 Not yet recruiting A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD.
Condition: Chronic Obstructive Pulmonary Disorder
Interventions: Drug: BFF MDI 320/9.6 μg;   Drug: BFF MDI 160/9.6 μg;   Drug: FF MDI 9.6 μg;   Drug: BD MDI 320 μg

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years